Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H24N2O7 |
Molecular Weight | 332.3496 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12O[C@H](C)CC(=O)[C@]1(O)O[C@]3([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]3([H])O2
InChI
InChIKey=UNFWWIHTNXNPBV-WXKVUWSESA-N
InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including
http://www.jwatch.org/ac200604260000004/2006/04/26/spectinomycin-discontinued-treatment-gonorrhea
Curator's Comment: description was created based on several sources, including
http://www.jwatch.org/ac200604260000004/2006/04/26/spectinomycin-discontinued-treatment-gonorrhea
Spectinomycin is an antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae. In vitro studies have shown spectinomycin to be active against most strains of Neisseria gonorrhoeae (minimum inhibitory concentration <7.5 to 20 mcg/mL). Footprint studies indicate that spectinomycin exerts regional effects on ribosomal structure. Spectinomycin hydrochloride is an inhibitor of protein synthesis in the bacterial cell; the site of action is the 30S ribosomal subunit. The antibiotic is not significantly bound to plasma protein. Spectinomycin was discovered 1961. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. This antibiotic is no longer available in the United States. Pfizer has discontinued distribution of spectinomycin (Trobicin) in the U.S. The drug continues to be distributed outside the U.S.
CNS Activity
Originator
Sources: Applied microbiology (1961), 9, 524-8.
Curator's Comment: https://books.google.es/books?id=5Fv0BwAAQBAJ&pg=PA47&lpg=PA47&dq=spectinomycin+was+discovered+1961&source=bl&ots=tz5daI3o3n&sig=HdeWzppPEz7i1UZ7Y_zxMM7qsFo&hl=ru&sa=X&ved=0ahUKEwjX1YWN9NDPAhXE0hoKHc8mB5cQ6AEIJDAB#v=onepage&q=spectinomycin%20was%20discovered%201961&f=false
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11014183 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TROBICIN Approved UseTROBICIN Sterile Powder is indicated in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae. Men and women with known recent exposure to gonorrhea should be treated as those known to have gonorrhea. Launch Date1971 |
|||
Curative | TROBICIN Approved UseTROBICIN Sterile Powder is indicated in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae. Men and women with known recent exposure to gonorrhea should be treated as those known to have gonorrhea. Launch Date1971 |
|||
Curative | TROBICIN Approved UseTROBICIN Sterile Powder is indicated in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae. Men and women with known recent exposure to gonorrhea should be treated as those known to have gonorrhea. Launch Date1971 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100 μg/mL |
2 g single, intramuscular dose: 2 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
SPECTINOMYCIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
460 μg × h/mL |
2 g single, intramuscular dose: 2 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
SPECTINOMYCIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.7 h |
2 g single, intramuscular dose: 2 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
SPECTINOMYCIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% |
2 g single, intramuscular dose: 2 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
SPECTINOMYCIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Screening for new compounds with antiherpes activity. | 1984 Oct |
|
Comparison of in vitro antimicrobial susceptibilities of Mycobacterium avium-M. intracellulare strains from patients with acquired immunodeficiency syndrome (AIDS), patients without AIDS, and animal sources. | 1990 Jul |
|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones over time in Rwanda. | 1993 Jun |
|
Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. | 1993 Sep 24 |
|
In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria. | 1997 Jul |
|
[Regeneration of cybrid Lycopersicon peruvianum x (Solanum rickii) plants with genetically transformed chloroplasts]. | 2005 Nov-Dec |
|
[Stable transformation of Solanum rickii chloroplast DNA]. | 2005 Sep-Oct |
|
[Somatic hybrids among transgenic Solanum tuberosum and transplastomic Solanum rickii]. | 2008 Jul-Aug |
|
[E-test quantitative determination for evaluating Neisseria gonorrhoeae resistance]. | 2010 Oct-Dec |
|
Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. | 2011 Aug |
|
Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. | 2014 Feb |
Sample Use Guides
Adults (Men and Women)—Inject 5 mL intramuscularly for a 2-gram dose. This is also the recommended dose for patients being treated after failure of previous antibiotic therapy
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1605592
Antibiotic susceptibility surveillance testing was performed on clinical isolates of Neisseria gonorrhoeae collected in September 1989 in the Philippines. Spectinomycin resistance was rare (10 of 117), but the MIC90 was 32 micrograms/ml.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.2
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
CFR |
21 CFR 520.2123
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
CFR |
21 CFR 520.2123B
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
NCI_THESAURUS |
C2363
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
CFR |
21 CFR 520.2123C
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
WHO-VATC |
QJ01XX04
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
CFR |
21 CFR 520.2123A
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
CFR |
21 CFR 520.1265
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
CFR |
21 CFR 556.600
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
WHO-ATC |
J01XX04
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
93AKI1U6QF
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
270
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | RxNorm | ||
|
9217
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
1429
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
100000083820
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
SUB10614MIG
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
15541
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
C61951
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
216-911-3
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
DB00919
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
SPECTINOMYCIN
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL1167
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
146260
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
m10136
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
2468
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
1695-77-8
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
DTXSID9023592
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
D000198
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
9215
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
93AKI1U6QF
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)